February 18, 2026
Experts discuss next-gen CELMoDs in multiple myeloma, detailing their potent mechanism, trial data, and role in high-risk & extramedullary disease.
February 17, 2026
Experts discuss EV+pembro for metastatic bladder cancer, covering toxicity management, durable responses, and sequencing targeted therapies.
February 16, 2026
ESMO 2025 GYN cancer highlights: IO shows promise in platinum-resistant ovarian cancer, new ADCs emerge, and biomarker-driven therapy expands.
February 13, 2026
ASH 2025 myeloma review: Tekdara shows major survival benefit, belantamab's ocular toxicity is manageable, and BCL-2 inhibitors are promising.
February 12, 2026
Dr. Marwan Fakih discusses squamous cell carcinoma of the anal canal (SCAC), highlighting IO+chemo's impact and the potential for cure.
February 11, 2026
The PODIUM-303 trial establishes a new standard for advanced anal cancer: adding retifenlimab to chemo improves PFS, ORR, and overall survival.
February 10, 2026
ESMO 2025 prostate cancer update: The Embark trial's striking OS benefit sets a new standard, while PARP inhibitors show promise for earlier use.
February 9, 2026
Dr. Kathleen Moore discusses transformative ADCs in ovarian cancer, detailing their efficacy, unique toxicities like ILD, and future challenges.
ADCs are revolutionizing ovarian cancer treatment. Dr. Kathleen Moore discusses key targets (FRα, TROP2), new agents, and future challenges.
February 7, 2026
Experts discuss new paradigms in localized CRC: neoadjuvant IO for MSI-H, FOLFOX+atezo post-op, and ctDNA's role in guiding therapy.
February 6, 2026
Experts review ITP management from ASH 2025, covering TPO agonists, BTK inhibitors, and the promising new agent yanalumab.
February 5, 2026
ESMO 2025 bladder cancer updates: EVP shows major survival benefit in MIBC, durvalumab improves NMIBC outcomes, and ctDNA guides adjuvant IO.
February 3, 2026
ASH 2025 myeloma review: In vivo CAR-T shows promise, belantamab dosing gets flexible, siltacel data suggests cure, & new combos tackle tough cases.
February 2, 2026
Experts review pivotal data for zanidatumab (HER2) & zolbituximab (Claudin 18.2) in advanced gastroesophageal cancer management.
January 28, 2026
Experts discuss new HER2-targeted therapies like zanidatumab & TDXD for biliary, gastric, & colorectal cancers, covering new data & cases.
January 27, 2026
Experts review optimal endocrine strategies for ER+ breast cancer, from genomic assays and CDK4/6i to new PI3K inhibitors and oral SERDs.
January 21, 2026
ASH 2025 review: Bispecific antibodies show durable responses and are moving to frontline lymphoma therapy with new combinations setting standards.
January 14, 2026
Experts debate new HER2+ breast cancer data, covering TDXD's role in neoadjuvant/1st-line settings, brain met management, and toxicity protocols.
Experts review ADCs (polatuzumab) and bispecifics in DLBCL & FL, debating sequencing, toxicity management, and their role vs. CAR-T therapy.
January 12, 2026
Circulating tumor DNA (ctDNA) is transforming colorectal cancer care, guiding adjuvant therapy, predicting benefit, and shaping future MRD trials.
January 10, 2026
Experts discuss managing myelofibrosis with tailored JAK inhibitors and novel agents, plus the complex diagnosis and treatment of systemic mastocytosis.
January 8, 2026
Experts discuss new ADC trial data for metastatic breast cancer, covering sacituzumab, TDXD, and datopotamab, and debating sequencing strategies.
January 7, 2026
Experts discuss the shift to targeted therapies in CLL, comparing BTKi and venetoclax, managing AEs, and sequencing for relapsed disease.
January 6, 2026
Tumor-informed ctDNA assays are transforming colorectal cancer care, enabling precise risk stratification and guiding adjuvant therapy decisions.
January 3, 2026
Experts discuss the future of AML management, focusing on fitness-based therapy, targeted agents for FLT3/IDH, and new menin inhibitors.
